US006316002B1

(12) **United States Patent**
Liu et al.

(10) **Patent No.: US 6,316,002 B1**
(45) **Date of Patent: Nov. 13, 2001**

(54) **GERMINATION ACTIVATED RED *GANODERMA LUCIDUM* SPORES AND METHOD FOR PRODUCING THE SAME**

(76) Inventors: **Xin Liu**, Building No. 391, 135 Xingang Xi Road, Guangzhou (CN); **Chee-Keung Chung**, Room 1505, Argyle Centre, 688 Nathan Rd., Mongkok, Kowloon (KR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/524,508**

(22) Filed: **Mar. 13, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/158,377, filed on Oct. 12, 1999.

(51) **Int. Cl.**[7] **A61K 35/00**; A61K 35/78

(52) **U.S. Cl.** **424/195.15**; 424/780

(58) **Field of Search** 424/195.15, 780

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,472,907	9/1984	Wada et al.	47/1.1
5,595,742 *	1/1997	Fujiwara et al. .	

FOREIGN PATENT DOCUMENTS

1101860 *	4/1995	(CN) .
1111529 *	11/1995	(CN) .
1118005 *	3/1996	(CN) .
1122658 *	5/1996	(CN) .
1134306A *	10/1996	(CN) .
1165032A *	11/1997	(CN) .
1245718 *	8/1998	(CN) .
1200286 *	12/1998	(CN) .
1205231 *	1/1999	(CN) .
1231925 *	10/1999	(CN) .
2240026	9/1990	(JP) .
52041208	8/1993	(JP) .

OTHER PUBLICATIONS

Jiang et al. Shipin Kexue (Beijing). vol. 17, No. 4, pp. 19–22, CAPLUS Abstract enclosed, 1996.*

Yang et al. Zhongcaoyao. vol. 28, No. 12, pp. 721–723, CAPLUS Abstract enclosed, 1997.*

Lee, Seung Y.; Cardiovascular Effects of Mycelium Extract of *Ganoderma lucidum*: Inhibition of Sympathetic Outflow as a Mechanism of Its Hypotensive Action, Chem Pharm. Bull. vol. 38, p. 1359–1364 (1990).

Kim et al., Int. J. Mol. Med vol. 4(3), p. 273–277 (1999).

Lin et al., J. Ethnopharmacol., vol. 47 (1), p. 33–41 (1995).

Mekkawy, SaHar et al., Anti-HIV-1 and Anti-HIV-A-Protease Substances from *Ganoderma Lucidum; Phytochemistry*, vol. 49(6), p. 1651–1657 (1998).

Wasser, Solomon P., et al., Therapeutic Effects of Substances Occurring in Higher Basidiomycetes Mushrooms: A Modern Perspective; *Crit. Rev. Immunol.*, vol. 19(1), p. 65–96 (1999).

Miyazaki, Toshio et al., Studies on Fungal Polysaccaridesxxvil Structual Examination of a Water–soluble, Antitumor Polysaccaride of *Ganoderma lucidum; Chem. Pharm. Bull.*, vol. 29(12), p. 3611–3616 (1981).

Min, Byung–Sun et al.; Triterpenes from the Spores of *Ganoderma lucidum* and Their Inhibitory Activity against HIV–1 Protease; *Chem. Phar. Bull.*, vol. 46(10), p. 1607–1612 (1998).

Kino, K. et al., An immunomodulating protein, Ling Zhi–8(LZ–8) prevents insulitis an non–obese diabetic mice; *Diabetolgia*, vol. 33, p. 713–718 (1990).

Lieuwe, G. et al.; Ling Zhi–8: Studies of a New Immunomodulating Agent; *Transplantation*, vol. 60, p. 438–443 (1995).

Kino, Kohsuke et al.; Immunomodulator, LZ–8, Prevents Antibody Production in Mice; *Int. J. Immunopharmac.*, vol. 13(8), p. 1109–1115 (1991).

Maruyama, Hirofumi; Antitumor Activity of *Sarcodon aspratus* (BERK>)S. Ito and *Ganoderma lucidum* (FR.) Karst.; *J. Pharmacobio–Dyn.*, vol. 12, p. 118–123 (1989).

Shimizu, Akria et al.; Isolation of an Inhibitor of Platelet Aggregation from a Fungus, *Ganoderma lucidum; Chem. Pharm. Bull.*, vol. 33, p. 3012–3015 (1985).

Morigiwa, Aiko et al.; Angiotension Converting Enzyme–Inhibitory Triterpenes from *Ganoderma lucidum; Chem. Pharm. Bull.*, vol. 34(7), p. 3025–3028 (1986).

Kanmatsuse, Katsuo et al.; Studies of *Ganoderma lucidum*. I. Efficacy against Hypertension and Side Effects; *Yakugaku Zasshi*, vol. 105(10), p. 942–947 (1985).

Lieu, Chien–Whei et al.; The Effect of *Ganoderma lucidum* on Induction of Differentiation in Leukemic U937 Cells; *Anticancer Research*, vol. 12, p. 1211–1216 (1992).

(List continued on next page.)

Primary Examiner—Christopher R. Tate
(74) *Attorney, Agent, or Firm*—Fei-Fei Chao; Venable, Baetjer, Howard & Civiletti, LLP

(57) **ABSTRACT**

The present invention describes a method for germination activating spores of red Ganoderma lucidum to produce bioactive substances which has medicinal effects on patients with immunological disorders, cancer, AIDS, hepatitis, diabetes, and cardiovascular diseases, and can prevent or inhibit free radical oxidation and hepatotoxic effects. The method can be subdivided into three stages. At the first stage, a germination activation method is introduced which includes soaking the spores in a solution to induce germination, and placing the germination treated spores in a culture box to induce the synthesis of bioactive substances and softening of the cell walls of the spores. At the second stage, sporoderm-broken ganoderma spores are collected by treating the epispores with cell wall breaking enzymes and/or mechanical force. At the last stage, the bioactive substances are extracted from the sporoderm-broken spores by drying at low temperature followed by extraction.

22 Claims, No Drawings